Business

Ratnaveer Precision Engineering Hits Fresh 52-Week High at Rs. 223.75; Stock Gains 24.65% in a Month

Aug 14, 2026

BusinessWire India
Vadodara (Gujarat) [India], August 14: Ratnaveer Precision Engineering Limited witnessed a strong technical breakout, with its stock touching a fresh 52-week high of Rs. 223.75, marking the third new 52-week high recorded during the month.
The stock has delivered a 24.65% return over the past one month, reflecting sustained buying momentum and improving market sentiment. The latest breakout above its recent trading range further strengthens the stock's positive technical structure.
Adding to the company's growth outlook is its Copper Clad Laminate (CCL) project, which is currently around 60% complete, with commercial production targeted for November 2026. The project, entailing an investment of approximately Rs. 472.34 crore, is expected to expand Ratnaveer's presence into the growing electronics materials segment.
The continued creation of fresh highs, coupled with progress on the CCL project and the company's broader business growth initiatives, highlights growing investor interest in Ratnaveer Precision Engineering, making it a key counter to watch in the precision engineering and stainless-steel manufacturing space.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by BusinessWire India. ANI will not be responsible in any way for the content of the same)

More news

India's TB elimination goal needs stronger diagnostic infrastructure at the point of care: peer-reviewed study

New Delhi [India], August 14: India's fight against tuberculosis needs to go beyond treatment and case notification and urgently focus on strengthening diagnostic infrastructure at the point of care, according to a new peer-reviewed study published in Microbiology Spectrum, a journal of the American Society for Microbiology. The study, titled "Evaluating the nationwide availability of essential diagnostics for tuberculosis towards achieving a TB-free India," provides a multi-state assessment of essential tuberculosis diagnostic services across public-sector healthcare facilities and a nationwide analysis of TB Treatment Units and Culture and Drug Susceptibility Testing (CDST) laboratories. The research team assessed 327 healthcare facilities across seven states and Delhi, while also analysing national-level data on TB Treatment Units and CDST laboratories.

Aug 14, 2026